S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
S&P 500   3,851.85
DOW   31,188.38
QQQ   324.93
Log in

TCR2 Therapeutics Stock Forecast, Price & News

-0.90 (-2.85 %)
(As of 01/20/2021 12:00 AM ET)
Today's Range
Now: $30.72
50-Day Range
MA: $30.92
52-Week Range
Now: $30.72
Volume1.96 million shs
Average Volume529,904 shs
Market Capitalization$1.03 billion
P/E RatioN/A
Dividend YieldN/A
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Overall MarketRank

1.53 out of 5 stars

Medical Sector

642nd out of 1,928 stocks

Biological Products, Except Diagnostic Industry

83rd out of 177 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:TCRR



Sales & Book Value

Annual SalesN/A
Book Value$6.68 per share


Net Income$-47,600,000.00


Market Cap$1.03 billion
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
-0.90 (-2.85 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TCRR News and Ratings via Email

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

TCR2 Therapeutics (NASDAQ:TCRR) Frequently Asked Questions

How has TCR2 Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

TCR2 Therapeutics' stock was trading at $8.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TCRR stock has increased by 258.0% and is now trading at $30.72.
View which stocks have been most impacted by COVID-19

Is TCR2 Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TCR2 Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TCR2 Therapeutics stock.
View analyst ratings for TCR2 Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than TCR2 Therapeutics?

Wall Street analysts have given TCR2 Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but TCR2 Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as TCR2 Therapeutics' CEO?

1,428 employees have rated TCR2 Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among TCR2 Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is TCR2 Therapeutics' next earnings date?

TCR2 Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for TCR2 Therapeutics

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) announced its quarterly earnings data on Thursday, November, 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.52) by $0.04.
View TCR2 Therapeutics' earnings history

What price target have analysts set for TCRR?

7 brokerages have issued 12 month price objectives for TCR2 Therapeutics' stock. Their forecasts range from $25.00 to $65.00. On average, they expect TCR2 Therapeutics' share price to reach $39.29 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts' price targets for TCR2 Therapeutics
or view Wall Street analyst' top-rated stocks.

Who are some of TCR2 Therapeutics' key competitors?

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TCR2 Therapeutics investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), Precision BioSciences (DTIL), Homology Medicines (FIXX), LogicBio Therapeutics (LOGC), Sorrento Therapeutics (SRNE), Atreca (BCEL) and II-VI (IIVI).

Who are TCR2 Therapeutics' key executives?

TCR2 Therapeutics' management team includes the following people:
  • Dr. Garry E. Menzel M.B.A., Ph.D., Pres, CEO & Director (Age 56, Pay $775.38k)
  • Mr. Mayur Amrat Somaiya, Chief Financial Officer (Age 47, Pay $523.91k)
  • Dr. Alfonso Quintás Cardama M.D., Chief Medical Officer (Age 49, Pay $595.46k)
  • Mr. Robert Hofmeister Ph.D., Chief Scientific Officer (Age 52)
  • Carl Mauch, Director of Investor Relations & Corp. Communications
  • Ms. Margaret Siegel, Head of Legal & Corp. Sec.
  • Dr. Angela Justice Ph.D., Chief People Officer (Age 48)
  • Mr. Gregg McConnell M.B.A., Head of Bus. Devel.
  • Mr. Stephen Turkowiak M.B.A., VP of Fin. & Treasurer

When did TCR2 Therapeutics IPO?

(TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at a price of $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What is TCR2 Therapeutics' stock symbol?

TCR2 Therapeutics trades on the NASDAQ under the ticker symbol "TCRR."

Who are TCR2 Therapeutics' major shareholders?

TCR2 Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own TCR2 Therapeutics stock include Mayur Ian Somaiya, Morana Jovan-Embiricos, Neil W Gibson, Robert Hofmeister and Upnorth Investment Ltd.
View institutional ownership trends for TCR2 Therapeutics

Which major investors are buying TCR2 Therapeutics stock?

TCRR stock was bought by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have bought TCR2 Therapeutics stock in the last two years include Morana Jovan-Embiricos, and Upnorth Investment Ltd.
View insider buying and selling activity for TCR2 Therapeutics
or or view top insider-buying stocks.

How do I buy shares of TCR2 Therapeutics?

Shares of TCRR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TCR2 Therapeutics' stock price today?

One share of TCRR stock can currently be purchased for approximately $30.72.

How big of a company is TCR2 Therapeutics?

TCR2 Therapeutics has a market capitalization of $1.03 billion. The company earns $-47,600,000.00 in net income (profit) each year or ($4.62) on an earnings per share basis. TCR2 Therapeutics employs 109 workers across the globe.

What is TCR2 Therapeutics' official website?

The official website for TCR2 Therapeutics is www.tcr2.com.

How can I contact TCR2 Therapeutics?

TCR2 Therapeutics' mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-949-5200 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.